After 25 years, the American Medical Association (AMA) Current Procedural Terminology (CPT) office and outpatient evaluation and management (E/M) codes received a major overhaul. These changes, which went into effect Jan. 1, will help reduce administrative burden on providers and roll back some of the rigid requirements for E/M coding by simplifying the code selection…
Experts discussed the latest knowledge on B cell disease processes, and what it might mean for future B cell depletion therapies.
NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…
At the virtual interim meeting Nov. 13–17, the ACR delegation led a successful bid to update American Medical Association policies on home infusion and copay accumulators and supported efforts against the Most Favored Nation drug pricing model.
Speakers at ACR Convergence 2020 offered a range of tips to navigate the competitive environment of research funding, emphasizing the importance of collaboration, diversifying funding sources and staying determined in the face of disappointment.
NEW YORK (Reuters Health)—Barrett’s esophagus is common in women with systemic sclerosis or scleroderma (SSc) and is often accompanied by dysplasia, according to the largest study on prevalence of Barrett’s esophagus in women with SSc. In Barrett’s esophagus, chronic gastric reflux causes the lining the esophagus to be replaced by metaplastic cells that may lead…
Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
Dr. Kuhn hopes to expand funding for rheumatology research and enhance the ACR’s basic and clinical research pre-conference offerings during her term as chair.
Patients who do not fulfill classification criteria for systemic lupus erythematosus (SLE) can be referred to as having probable SLE (pSLE). These patients can be identified with cell-bound complement activation products (CB-CAPs), according to a recently published study in Arthritis & Rheumatology.1 The findings are relevant because the existing Systemic Lupus Erythematosus International Collaborating Clinics…
Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. Many biologic agents, particularly…